

Amendments to the Claims:

Claims 1-5 (Canceled)

6. (Currently Amended) A transgenic mouse whose genome comprises a null N-formylpeptide receptor-like 4 (FPR-RS4) allele, wherein the null allele comprises exogenous DNA.

Claim 7 (Canceled)

8. (Currently Amended) A cell ~~derived~~ isolated from the transgenic mouse of claim 6.
9. (Previously presented) A method of producing a transgenic mouse of claim 6, the method comprising:
- (a) introducing a construct that targets the FPR-RS4 gene into a mouse embryonic stem cell;
 - (b) introducing the embryonic stem cell into a blastocyst;
 - (c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and
 - (d) breeding the chimeric mouse to produce the transgenic mouse.

Claims 10-34 (Canceled)

35. (Previously presented) The transgenic mouse of claim 42, wherein the increased anxiety is characterized by decreased time spent in a central region during an open field test.
36. (Previously presented) The transgenic mouse of claim 42, wherein the decreased coordination is characterized by decreased time to fall during a rotarod test.
37. (Previously presented) The transgenic mouse of claim 42, wherein the decreased coordination is characterized by a decrease in time to fall off the accelerating rotarod.
38. (Previously presented) The transgenic mouse of claim 42, wherein the decreased coordination comprises impaired motor coordination, impaired balance, or ataxia.
39. (Previously presented) The transgenic mouse of claim 42, wherein the decreased susceptibility to seizure is characterized by an increased dose of metrazol to reach seizure.
40. (Previously presented) The transgenic mouse of claim 6 wherein said mouse is heterozygous for said null allele.
41. (Previously presented) The transgenic mouse of claim 6 wherein said mouse is homozygous for said null allele.
42. (Currently Amended) The transgenic mouse of claim ~~6-41~~ wherein said mouse exhibits, relative to a wild-type -control mouse, at least onea phenotype selected from the group

consisting of increased anxiety, decreased coordination, impaired balance and decreased susceptibility to seizure.

43. (Currently Amended) The transgenic mouse of claim 6 wherein ~~the said~~ endogenous FPR-RS4 ~~allele encodes mRNA comprising~~ comprises the sequence of SEQ ID NO:1.
44. (Currently Amended) The transgenic mouse of claim 6 wherein said exogenous DNA ~~comprises~~ encodes a gene encoding a selection marker.
45. (Currently Amended) The transgenic mouse of claim 44 wherein said gene encoding a selection marker is a neomycin resistance gene.
46. (Currently Amended) The transgenic mouse of claim 6 wherein said exogenous DNA ~~comprises a gene encoding~~ encodes a visible marker.
47. (Currently Amended) The transgenic mouse of claim 46 wherein said gene encoding a visible marker is a lacZ gene.